De-Escalating DAPT to Ticagrelor Monotherapy Cuts Bleeding Risk in Acute Coronary Syndrome

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 19, 2025.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Feb. 19, 2025 -- For patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation, de-escalating dual antiplatelet therapy (DAPT) to P2Y12 inhibitor monotherapy is associated with lower bleeding risk, without an increase in ischemic events, according to a review published online Feb. 18 in the Annals of Internal Medicine.

Yong-Joon Lee, M.D., from Severance Hospital at the Yonsei University College of Medicine in Seoul, South Korea, and colleagues compared the effects of de-escalating DAPT to ticagrelor monotherapy versus standard DAPT using data from randomized clinical trials involving patients with ACS. Individual patient data were obtained from three trials, including 9,130 randomized patients with ACS: 3,132 with ST-segment elevation myocardial infarction (STEMI); 3,023 with non-STEMI (NSTEMI); and 2,975 with unstable angina.

The researchers found no difference in the rate of the primary ischemic end point (composite of death, nonprocedural [spontaneous] myocardial infarction, or stroke) between the ticagrelor monotherapy and standard DAPT groups (1.7 versus 2.1 percent; hazard ratio, 0.85; 95 percent confidence interval, 0.63 to 1.16). The ticagrelor monotherapy group had a lower rate of the primary bleeding end point (0.8 versus 2.5 percent; hazard ratio, 0.30; 95 percent confidence interval, 0.21 to 0.45). The findings were consistent across STEMI, NSTEMI, and unstable angina.

"Our findings suggest that de-escalating DAPT to ticagrelor monotherapy will reduce aspirin-associated major bleeding while preserving the anti-ischemic benefits of antiplatelet therapy for patients with ACS of all types undergoing DES implantation," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-02-20 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords